Christine Mikail was appointed Director of Neurogene Inc. As of November 6, 2026, Neurogene Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 20, 2026, naming 1 appointment (Form 8-K, April 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Neurogene Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Neurogene Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-20. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Neurogene Inc. files it.
Also on the record for Neurogene Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G, by PRUDENTIAL FINANCIAL INC | 11.2% of the class | 5%+ stakes | Source |
| October 6, 2026 | Stake report, Schedule 13G, by Jennison Associates LLC | 11.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by BALYASNY ASSET MANAGEMENT L.P. | 5.18% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Trails Edge Capital Partners, LP | 4.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 5.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Baker Bros. Advisors LP | 7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Commodore Capital LP | 3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Neurogene Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Neurogene Inc. and the records around it.
Neurogene Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Nurix Therapeutics, Inc. (Aug 2026)
Watch Neurogene Inc.
Get an email when Neurogene Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neurogene Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Neurogene Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neurogene Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-20 | In | Director | 8-K, 2026-04-20 |
Who leads Neurogene Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Christine Mikail, appointed (filed 2026-04-20).
New leaders reset buying decisions — get the Full Report on Neurogene Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Neurogene Inc., with the record behind each one.
Find candidates like Director at Neurogene Inc.Every change, in the filing's words
Appointed: Christine Mikail, Director
Ms. Mikail was appointed as a Class II director for a term that will expire at the 2028 annual meeting of the Company's stockholders.
- Effective as of April 20, 2026, the Board of Directors (the "Board") of Neurogene Inc. (the "Company"), upon recommendation of the Board's Nominating and Corporate Governance Committee (the "Nominating Committee"), took action pursuant to the Company's Amended and Restated Bylaws to expand the Board to seven directors and appoint Christine Mikail, the Company's President and Chief Financial Officer, to fill the vacancy created by that expansion.
- Ms. Mikail has served as the Company's President and Chief Financial Officer since December 2023, and as President and Chief Financial Officer of the Company's wholly owned operating subsidiary, Neurogene Inc., a Nevada corporation ("Neurogene OpCo" and together with the Company, "Neurogene"), since September 2019 and as a member of the board of directors of Neurogene OpCo since December 2023.
- Ms. Mikail leads Corporate Strategy and Business Development, Portfolio Management, Operations, and Finance at the Company.
- Ms. Mikail brings over two decades of experience supporting biotechnology and pharmaceutical companies in corporate strategy and business development, operations, legal and finance capacities.
Tools for this story
Each opens in a new tab, filled in for Neurogene Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.